Braveheart Bio's IPO
Listed Aug 6, 2026 at $18 on Nasdaq as BRVE.
Today 22% above its $18 offer price; its first day closed +65.6%.
Breakaway does the work for you: insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Wednesday morning. No account. No card. Then keep going with a free account.
What does Braveheart Bio do?
“We are a clinical‑stage biopharmaceutical company focused on developing therapies for patients with hypertrophic cardiomyopathy ("HCM") and other serious cardiovascular diseases.”
| Fact | Braveheart Bio |
|---|---|
| Incorporated | Delaware, 2024 |
| Headquarters | San Francisco, California |
| Employees | 30 full-time, as of May 31, 2026 |
| Website | braveheart.bio |
What is the offering?
Each figure names the filing it is from and that filing's date. The market cap is Breakaway's arithmetic from the prospectus's share count.
| Fact | Braveheart Bio |
|---|---|
| Shares offered | 21,250,000 |
| Offer price | $18 a share |
| Raised at that price | $383 million |
| Underwriters' discount | $26.8 million |
| Net proceeds the company expects | About $351 million |
| Underwriters' option | 3,187,500 more shares |
| Underwriters | Goldman Sachs, Jefferies, TD Cowen, Stifel, Cantor, and August 5, 20 26 |
| Exchange | Nasdaq Global Market, as BRVE |
| Shares outstanding after | 73,152,838 |
| Market cap at the offer price | $1.32 billion |
What the filing says about its money
| Fact | Braveheart Bio |
|---|---|
| Revenue | None from product sales yet |
| Net loss | $66.1 million, year to December 31, 2025 |
| Last preferred stock | Series A preferred |
| Raised before the IPO | $125 million in private financings |
What risks does Braveheart Bio name first?
- “We are a clinical-stage biopharmaceutical company with a limited operating history, have incurred significant operating losses since inception, anticipate that we will continue to incur significant operating losses for the foreseeable future, and we may never achieve or maintain profitability.”
- “Even if this offering is successful, we will need substantial additional funding.”
- “We rely on clinical data generated by Hengrui from clinical trials that were not designed or conducted by us, and such data may not be adequate to support our regulatory submissions or future clinical development plans.”
Every date of Braveheart Bio's IPO
| What | Day |
|---|---|
| Registration filed | Jul 15, 2026 |
| Exchange registration filed | Aug 3, 2026 |
| Declared effective by the SEC | Aug 5, 2026 |
| Priced | Aug 6, 2026 |
| First trade | Aug 6, 2026 |
| Lock-up ends | Feb 1, 2027, at the latest |
How did its first days trade?
From its daily bars, each close against its $18 offer price.
| Day | Open | Close | From the offer |
|---|---|---|---|
| Aug 6 | $30.20 | $29.80 | +65.6% |
| Aug 7 | $29.70 | $30 | +66.7% |
| Aug 10 | $30.78 | $27.53 | +52.9% |
| Aug 11 | $27.53 | $25.01 | +38.9% |
| Aug 12 | $24.90 | $26.15 | +45.3% |
What is Braveheart Bio's Quality Score?
Below Average
BRVE's page, with every reason behind its scoreThe other IPOs expected
| Company | Price |
|---|---|
| $19 to $21 | |
| $15 to $17 | |
| $15 to $17 | |
| $7 | |
| $5 to $7 |
Braveheart Bio IPO questions
When is Braveheart Bio's IPO?
Listed Aug 6, 2026 at $18 on Nasdaq as BRVE.
What is Braveheart Bio's IPO price?
Braveheart Bio's IPO priced at $18 a share, per its final prospectus of Aug 6, 2026.
How many shares is Braveheart Bio selling?
21,250,000 shares, and the underwriters may buy 3,187,500 more, per its final prospectus (424B4).
Who are the underwriters?
Goldman Sachs, Jefferies, TD Cowen, Stifel, Cantor, and August 5, 20 26, as the prospectus's cover names them.
When does the lock-up end?
Braveheart Bio's IPO lock-up ends Feb 1, 2027 at the latest; its prospectus lets it end sooner on the terms it sets out. Its final prospectus says: “.”
Does Breakaway rate Braveheart Bio?
Braveheart Bio has a Quality Score of 5 today. The score counts the 14 chart checks and the company's filings; a check that needs more history than a new stock has waits for it.
Can Breakaway say where Braveheart Bio's price will go?
No. Breakaway does not say where a price will go. Every figure here is from the company's SEC filings, linked on each line.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Every new listing, ranked live, free. No account.
See all 16 new listings rankedSee it live, free until Wednesday morning. No account. No card. Then keep going with a free account.